IRLAB Therapeutics - Phase IIb trial patient follow-up as expected
IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in its Phase IIb study investigating mesdopetam in the treatment of patients with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). We see this as a significant milestone for the trial as IRLAB now looks to complete the data package following completion of the treatment period and to report top-line results in mid-January 2023. We had previously communicated that initial top-line readouts from the study would be disclosed around Q422. However, we do not see this as having any major impact on mesdopetam’s developmental timeline in PD-LIDs. We value IRLAB at SEK6.72bn or SEK129.8 per share.IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson's disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.